Narcolepsy-cataplexy syndrome

This trial tests an experimental oral drug, TAK-861, in people with narcolepsy type 1, a condition that causes severe daytime sleepiness and sudden muscle weakness (cataplexy). Researchers will compare TAK-861 against a placebo to see if it improves alertness and reduces cataplex…

This study tests whether clarithromycin, an antibiotic, can reduce excessive daytime sleepiness in people with narcolepsy or idiopathic hypersomnia. Participants receive either clarithromycin or a placebo for 14 days. Researchers will measure changes in sleepiness, brain activity…

This study compares a new mass spectrometry technique to the standard radioimmunoassay for measuring orexin-A levels in cerebrospinal fluid. Orexin-A is a key brain chemical that is low in people with type 1 narcolepsy. The study involves 117 people with excessive daytime sleepin…

This study tested a headband called Dreem 3S that people wear at home to monitor sleep and wake patterns. The goal was to see if it can help diagnose narcolepsy, a condition that causes extreme daytime sleepiness. 78 adults took part, and researchers checked how well the device w…

This study tested an experimental drug called TAK-861 in 105 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants took either TAK-861 or a placebo daily for 3 months. The main goal was to see if the drug…

This study tests two behavioral therapies—imagery rehearsal therapy (IRT) and targeted dream control (TDC)—to reduce nightmares in adults with narcolepsy. Participants attend therapy sessions, keep a daily sleep log, and complete questionnaires. Some Chicago-area participants als…

This Phase 2 trial tested AXS-12 (reboxetine) in 21 adults with narcolepsy and cataplexy. Participants received either the drug or a placebo for three weeks, then switched. The goal was to see if AXS-12 could reduce weekly cataplexy attacks and improve excessive daytime sleepines…

This study tested a new medicine called ALKS 2680 in 92 adults with narcolepsy type 1, a condition that causes severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants stopped their usual narcolepsy medications and received either ALKS 2680 or a placebo for …

This study tested a six-session behavioral therapy that teaches people with narcolepsy type 1 how to become aware during dreams (lucid dreaming) and control frightening images. Ninety-eight adults took part, with half receiving the therapy and half getting standard care. The goal…

This study tested an experimental drug called AXS-12 (reboxetine) in 90 people with narcolepsy who experience cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Participants took either the drug or a placebo twice daily for several weeks. The main goal was to se…

This early-phase study tested a new slow-release form of pitolisant (HBS-201) in 46 adults with narcolepsy. The goal was to see if starting at a full dose is tolerable. Participants took the drug for 14 days, and researchers tracked side effects and dropouts.

Idiopathic hypersomnia causes severe daytime sleepiness that differs from narcolepsy, yet researchers do not know what drives it. This study uses 64-electrode EEG to look for local slow waves, a sign of sleep-like activity in parts of an otherwise awake brain, while participants …

This study tested a website designed to help teenagers with narcolepsy or idiopathic hypersomnia and their families understand and improve social relationships. Twenty-five teens and their parents reviewed the website's content, which included animations, patient stories, and exp…